The Food and Drug Administration (FDA) has approved the use of this new vaccine in older adults. It is the second to be accepted.
After the Covid-19 pandemic, the new bronchiolitis flare began to worry specialists. However, the last month brought good news. The United States Food and Drug Administration (FDA) approved the use of a new vaccine against the respiratory virus.
It is the second formula accepted, since a month ago the GlaxoSmithKline Pharmaceutical. In this case, the vaccine is from the laboratory Pfizer, and will be granted exclusively to older adults. According to the medical company, it is 85% effective in preventing serious cases of the disease.
For its part, GlaxoSmithKline reported an effectiveness of 83% in the prevention of lower respiratory tract infections, and mild side effects, such as fatigue, muscle pain or headaches. For now, neither of the two doses is available in Argentina.
image.png
What is bronchiolitis and how does it work?
Respiratory syncytial virus (RSV) is a highly contagious virus known to cause bronchiolitis, or infection of the bronchioles in Small children and older adults in the winter. In minors it usually causes mild symptoms, but for adults it can be complicated, and even cause death.
However, bronchiolitis is the most important cause of respiratory tract infection lower in babies under one year of age worldwide. The virus that causes it circulates more intensely between april and septemberthat is, during the cold months.
During the stage of the disease, the bronchi are obstructed by inflammation and mucosa. The process usually takes between 7 and 12 daysbut it is from the second or third day when it can get worse.
Source: Ambito
